Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU14-202

Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer with Enzalutamide and the Poly (ADP-Ribose) Polymerase [PARP] Inhibitor Niraparib.

Status: Closed to Accrual

This is a phase I study to determine the safety and feasibility of the combination of enzalutamide and niraparib in subjects with metastatic castration-resistant prostate cancer (CRPC).

  • Condition:
    • Metastatic Prostate Cancer
  • Intervention:
    • Drug: Enzalutamide
    • Drug: Niraparib
  • Phase: Phase 1

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • J.P. Flores, P. Mathew. Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202. Accepted as a trials in progress poster session at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr TPS5095). See abstract.

Project Manager: Michael Nunley, mnunley@hoosiercancer.org; (317) 634-5842, ext. 17.